Radius Health

Radius Health is a global biopharmaceutical company focused on addressing unmet medical needs in the area of bone health.

[Radius Health @Radius_Health]

Radius Health is NOW Part of Paratek Pharmaceuticals
Learn more about our company and growing commercial portfolio of differentiated specialty medicines for patients with significant medical needs: https://t.co/I17LGjcGG4

[Radius Health @Radius_Health]

Hear Dr. Richard Eastell describe recent results on #bone turnover markers as a way to predict changes in bone mineral density in #men with #osteoporosis published in #JBMR https://t.co/PPaqd1UzAO

[Radius Health @Radius_Health]

Radius is proud to celebrate World Quality Day! It’s a time to reflect on the processes, practices, and commitment required to ensure excellence in all that we do. #WorldQualityDay
https://t.co/TA6ZxegNPS

[Radius Health @Radius_Health]

We are presenting #newdata at #ENDO2024 @TheEndoSociety on #BoneTurnoverMarkers #oralcommunication on June 2nd at 1:45 PM, 257ABC and #MalePredictiveModel #poster on June 3rd at 12PM abstract 7459 #Osteoporosis #BoneHealth

[Radius Health @Radius_Health]

White is the color of #OsteoporosisAwareness, and our team represented by wearing white on the same day to show our support for bone health. Here are just some of our team members who participated - both in person and virtually!

[Radius Health @Radius_Health]

At Radius, we embrace the importance of #collaboration and #givingback, and last week's offsite was no exception. We came together, to build #bikes as a team. The bikes were then donated to the Phoenixville Community Education Foundation that supports low income families.

[Radius Health @Radius_Health]

We are presenting new #RWE data on #hipfracture at #WCO2024 #IOF-ESCO #oralcommunication on April 12 at 10am GMT in the Auditorium A
Presented by: Professor JY Reginster

[Radius Health @Radius_Health]

Radius is excited to be at #WCO2024 #IOF-ESCO raising awareness on #osteoporosis and #hipfracture in #postmenoposalwomen

[Radius Health @Radius_Health]

Our partner in Japan, Teijin Pharma, announced that they have launched #abaloparatide for #osteoporosis in Japan. Read the full release here: https://t.co/jbwMwZSv4N

[Radius Health @Radius_Health]

Stemline Therapeutics Inc. receives approval from U.S. #FDA for ORSERDU (#elacestrant) as the first and only treatment specifically indicated for patients with ESR1 Mutations in ER+, HER2- advanced or metastatic breast cancer.

Read the full release here: https://t.co/4rGlgKg3DI

[Radius Health @Radius_Health]

Today we are proud to announce the U.S. FDA has approved our treatment to help men with osteoporosis. For more information, visit https://t.co/I17ZFwWqPP #FDA #Osteoporosis

[Radius Health @Radius_Health]

On #worldosteoporosisday – and every day – Radius is committed to bone health. If you suffer a broken bone over the age of 50, take #actionforbonehealth and ask your doctor for post-fracture care to help prevent secondary fractures.

[Radius Health @Radius_Health]

Worldwide, 1 in 3 women over age 50 will experience an osteoporotic fracture. Radius continues its commitment to bone health and on #worldosteoporosisday we urge everyone to take #actionforbonehealth.

[Radius Health @Radius_Health]

Gurnet Point Capital and Patient Square Capital Complete Their Acquisition of Radius Health, Inc.
https://t.co/l1gQGxjAwd

[Radius Health @Radius_Health]

Today we announced the first #patient has been randomized in the #RAD011 Phase 2/3 pivotal study for Prader-Willi Syndrome. https://t.co/aJwoe1osPc

#praderwillisyndrome
#PWS
#SCOUT015
@PWSAUSA
@ipwso
@fpwr

[Radius Health @Radius_Health]

Today Radius Health announced an agreement to be acquired by Gurnet Point Capital and Patient Square Capital.

Radius will host a call at 9:30 a.m. ET today to review the proposed transaction.

Read the press release here https://t.co/cET4yjtyQJ

[Radius Health @Radius_Health]

Along with Menarini Group, today we announced a New Drug Application submission to the #FDA for #elacestrant in patients with ER+/HER2- advanced or metastatic breast cancer.

Read the full release here: https://t.co/Zw9i68AB9W

#nda
#oncology

[Radius Health @Radius_Health]

Radius continues its focus on the global business expansion of TYMLOS (abaloparatide) subcutaneous injection. Today we announced that we have entered agreements that add 13 new countries to the current non-US markets of Japan and Canada. https://t.co/qSQ3J719Nd

[Radius Health @Radius_Health]

Menarini Group and Radius Health, Inc. present a subgroup analysis from the elacestrant pivotal phase 3 #EMERALD clinical trial at the @ASCO 2022 Annual Meeting https://t.co/YBhr2kh2v2
#ASCO22
#oncology

[Radius Health @Radius_Health]

Today we provided an update on the abaloparatide transdermal system development program.
Read the full release below.
https://t.co/e8R7HlEZtN